Company profile
Enanta Pharmaceuticals, Inc.
NASDAQ: ENTA · Healthcare · Biotechnology
#402 of 1,422 Healthcare companies by revenue36th-percentile growth
EA Score
55CFH 46DQ 66GM 52SS 66
v0.1 · 65/100 weight · provisional
↑ growth stability, disclosure history · ↓ return on equity, 3-yr revenue growth
Methodology →Revenue TTM
$69.2M
Rev growth YoY (TTM)
+7.4%
Net income (FY)
-$81.9M
Employees
120
as of 2026-08-12
Market cap
$393.1M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$65.3M$65.3M2025
Net income-$81.9M-$81.9M2025
Operating income-$85.3M-$85.3M2025
Total assets$280.7M$280.7M2025
Liabilities$216.0M$216.0M2025
Equity$64.7M$64.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Royalty100%
By geography
Not disclosed.
The read
What is Enanta Pharmaceuticals, Inc.’s revenue?
Enanta Pharmaceuticals, Inc. booked $65.3M in FY2025 revenue, contracting 3.4% year over year — slower than 64% of Healthcare companies we track, at a -125.4% net margin.
Peers · Healthcare
Pro-Dex, Inc.86AExagen Inc.55CAytu BioPharma, Inc.53DCosmos Health Inc.55CConcord Medical Services Holdings Limited59CElectromed, Inc.80B+Neighbors
Middlesex →Key facts
CEOJay R. Luly
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
ExchangeNASDAQ: ENTA
Employees120
IPO date2013-03-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.